TRECs levels in PID patients after HSCT
We followed up TRECs levels in five patients with classical WAS and two with CGD who underwent HSCT (Fig. 9). The clinical features of these patients are summarized in Table 5. Patients P2 and P5 characterized by respiratory tract infections, eczema, and thrombocytopenia. P2 developed GVHD in the liver, eyes, and CNS after HSCT, and P5 suffered multiple organs disorders. P6 on set with systemic tuberculosis after BCG vaccination and suffered liver and kidney damage after HSCT. P2, P5, and P6 had low levels of TRECs up until 4 weeks after HSCT. The other four patients showed elevated TRECs levels in the following 4 weeks, which returned to the normal range at around 1 year post-HSCT.